ArticleClinical and molecular allergy : CMA2004
Low-dose, long-term macrolide therapy in asthma: An overview.
Article in Clinical and molecular allergy : CMA, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 36 citations in OpenAlex.
- Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.Thorax · 2006Trial
- Prophylactic macrolides for chronic obstructive pulmonary disease in the community: a decision for GPs.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022Article
- Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Article
- Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.Experimental and therapeutic medicine · 2015Article
- Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.European journal of clinical pharmacology · 2012Review
- Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.Mediators of inflammation · 2012Review
- Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis.Respiratory research · 2010Article
- Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma.The American journal of pathology · 2009Review
- Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells.American journal of physiology. Lung cellular and molecular physiology · 2008Article
- Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis.Paediatric drugs · 2007Review
- Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations.Allergy and asthma proceedingsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrolides, a class of antimicrobials isolated from Streptomycetes more than 50 years ago, are used extensively to treat sinopulmonary infections in humans. In addition, a growing body of experimental and clinical evidence indicates that long-term (years), low (sub-antimicrobial)-dose 14- and 15-membered ring macrolide antibiotics, such as erythromycin, clarithromycin, roxithromycin and azithromycin, express immunomodulatory and tissue reparative effects that are distinct from their anti-infective properties. These salutary effects are operative in various lung disorders, including diffuse panbronchiolitis, cystic fibrosis, persistent chronic rhinosinusitis, nasal polyposis, bronchiectasis, asthma and cryptogenic organizing pneumonia.The purpose of this overview is to outline the immunomodulatory effects of macrolide antibiotics in patients with asthma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.